Tatjana Slavoljub Radosavljević

Prof. Tatjana Slavoljub Radosavljević

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MVMilena Veskovic
Milena Veskovic
DMDusan Mladenovic
Dusan Mladenovic
MMMarina Milenkovic
Marina Milenkovic
JTJelena Tosic
Jelena Tosic
SBSuncica Borozan
Suncica Borozan
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević

26 July 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević
MBMilica Brankovic
Milica Brankovic
Janko SamardzicJanko Samardzic
Janko Samardzic
JDJasmina Djuretić
Jasmina Djuretić
DVDusan Vukicevic
Dusan Vukicevic
VJVladimir Jakovljevic
Vladimir Jakovljevic
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a range of liver conditions from steatosis to nonalcoholic steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis of MASLD involves metabolic dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role of mitochondrial dysfunction in MASLD’s progression. Therapeutically, enhancing mitochondrial function has gained interest, along with lifestyle changes and pharmacological interventions targeting mitochondrial processes. The FDA’s approval of resmetirom for metabolic-associated steatohepatitis (MASH) with fibrosis marks a significant step. While resmetirom represents progress, further research is essential to understand MASLD-related mitochondrial dysfunction fully. Innovative strategies like gene editing and small-molecule modulators, alongside lifestyle interventions, can potentially improve MASLD treatment. Drug repurposing and new targets will advance MASLD therapy, addressing its increasing global burden. Therefore, this review aims to provide a better understanding of the role of mitochondrial dysfunction in MASLD and identify more effective preventive and treatment strategies.

1 February 2014 in Journal of Medicinal Food
Verified
Journal Article
Closed access
MSMilena N. Stanković
Milena N. Stanković
DMDušan Mladenović
Dušan Mladenović
MNMilica Ninković
Milica Ninković
IÐIvana Ðuričić
Ivana Ðuričić
SŠSlađana Šobajić
Slađana Šobajić
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević
Development of nonalcoholic fatty liver disease (NAFLD) occurs through initial steatosis and subsequent oxidative stress. The aim of this study was to examine the effects of α-lipoic acid (LA) on methionine-choline deficient (MCD) diet-induced NAFLD in mice. Male C57BL/6 mice (n=21) were divided into three groups (n=7 per group): (1) control fed with standard chow, (2) MCD2 group--fed with MCD diet for 2 weeks, and (3) MCD2+LA group--2 weeks on MCD receiving LA i.p. 100 mg/kg/day. After the treatment, liver samples were taken for pathohistology, oxidative stress parameters, antioxidative enzymes, and liver free fatty acid (FFA) composition. Mild microvesicular hepatic steatosis was found in MCD2 group, while it was reduced to single fat droplets evident in MCD2+LA group. Lipid peroxidation and nitrosative stress were increased by MCD diet, while LA administration induced a decrease in liver malondialdehyde and nitrates+nitrites level. Similary, LA improved liver antioxidative capacity by increasing total superoxide dismutase (tSOD), manganese SOD (MnSOD), and copper/zinc-SOD (Cu/ZnSOD) activity as well as glutathione (GSH) content. Liver FFA profile has shown a significant decrease in saturated acids, arachidonic, and docosahexaenoic acid (DHA), while LA treatment increased their proportions. It can be concluded that LA ameliorates lipid peroxidation and nitrosative stress in MCD diet-induced hepatic steatosis through an increase in SOD activity and GSH level. In addition, LA increases the proportion of palmitic, stearic, arachidonic, and DHA in the fatty liver. An increase in DHA may be a potential mechanism of anti-inflammatory and antioxidant effects of LA in MCD diet-induced NAFLD.

1 February 2014 in Archives of Medical Research
Verified
Journal Article
Closed access
MSMilena N. Stanković
Milena N. Stanković
DMDušan R. Mladenović
Dušan R. Mladenović
IĐIvana Đuričić
Ivana Đuričić
SŠSlađana S. Šobajić
Slađana S. Šobajić
JTJasmina Timić
Jasmina Timić
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević

1 September 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
BJBojan Jorgačević
Bojan Jorgačević
SSSanja Stanković
Sanja Stanković
JFJelena Filipović
Jelena Filipović
JSJanko Samardžić
Janko Samardžić
DVDanijela Vučević
Danijela Vučević
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević
Background: Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with chemokine properties released by various immune and non-immune cells. It contributes to the pathogenesis of many inflammatory, autoimmune diseases and malignant tumors. Objective: Our study aimed to investigate the role of betaine in the modulation of MIF-mediated oxidative stress, inflammation, and fibrogenesis during toxic kidney damage induced by thioacetamide (TAA). Methods: The experiment is performed on wild-type and knockout MIF-/- C57BL/6 mice. They are randomly divided into groups: Control; Bet-group, received betaine (2% wt/v dissolved in drinking water); MIF-/- mice group; MIF-/- + Bet; TAA-group, treated with TAA (200 mg/kg b.w.), intraperitoneally, 3x/week/8 weeks); TAA+Bet; MIF-/-+TAA, and MIF-/- + TAA+Bet group. After eight weeks of treatment, animals are sacrificed and kidney samples are taken to determine oxidative stress parameters, proinflammatory cytokines, profibrogenic factors, and histopathology of renal tissue. Results: In MIF-/-mice, TAA decreases malondialdehyde (MDA) concentration, IL-6, tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta 1 (TGF-β1) and platelet-derived growth factor-BB (PDGF-BB) and increases superoxide dismutases (SOD) and catalase (CAT) activities, as well as glutathione (GSH) content in kidneys, compared to TAA group. Betaine alleviates the mechanism of MIF-mediated effects in TAA-induced nephrotoxicity, reducing MDA, IL-6, TNF-α, TGF-β1, and PDGF-BB, and increasing SOD and CAT activity, as well as GSH levels. Conclusion: MIF mediates TAA-induced nephrotoxicity by increasing oxidative stress, inflammation, and profibrogenic mediators. MIF-targeted therapy could potentially alleviate oxidative stress and inflammation in the kidney, as well as pathohistological changes in renal tissue, but the exact mechanism of its action is not completely clear. Betaine alleviates MIF nephrotoxic effects by increasing the antioxidative capacity of kidney cells, and decreasing lipid peroxidation and cytokine production in the renal tissue. It suggests that betaine can be used for the prevention of kidney damage.

15 October 2013 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
PDF file
BJB Jorgačević
B Jorgačević
DMD Mladenović
D Mladenović
MNM Ninković
M Ninković
VPV Prokić
V Prokić
MSMN Stanković
MN Stanković
Tatjana Slavoljub RadosavljevićTatjana Slavoljub Radosavljević
Tatjana Slavoljub Radosavljević
Insulin resistance, oxidative stress, and proinflammatory cytokines play a key role in pathogenesis of nonalcoholic fatty liver disease (NAFLD). The aim of our study was to investigate the dynamics of oxidative/nitrosative stress in methionine–choline-deficient (MCD) diet -induced NAFLD in mice. Male C57BL/6 mice were divided into following groups: group 1: control group on standard diet; group 2: MCD diet for 2, 4, and 6 weeks (MCD2, MCD4, and MCD6, respectively). After treatment, liver and blood samples were taken for histopathology, alanine- and aspartate aminotransferase, acute phase reactants, and oxidative/nitrosative stress parameters. Liver malondialdehyde level was higher in all MCD-fed groups versus control group (p < 0.01), while nitrites + nitrates level showed a progressive increase. The activity of total superoxide dismutase and its isoenzymes was significantly lower in all MCD-fed groups (p < 0.01). Although catalase activity was significantly lower in MCD-fed animals at all intervals (p < 0.01), the lowest activity of this enzyme was evident in MCD4 group. Liver content of glutathione was lower in MCD4 (p < 0.05) and MCD6 group (p < 0.01) versus control. Ferritin and C-reactive protein serum concentration were significantly higher only in MCD6 group. Our study suggests that MCD diet induces a progressive rise in nitrosative stress in the liver. Additionally, the most prominent decrease in liver antioxidative capacity is in the fourth week, which implies that application of antioxidants would be most suitable in this period, in order to prevent nonalcoholic steatohepatitis but not the initial NAFLD phase.